Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Image-based screening to enhance insulin production in human embryonic stem cells
FY 2016-17
Summary
Type 1 diabetes is a disease where the body's immune system attacks and destroys the cells in the pancreas known as beta-cells, which produce insulin. The resulting loss of insulin causes high blood glucose levels that can lead to long-term complications such as heart disease and stroke. Current treatment for patients involves monitoring of blood glucose levels and insulin injections many times each day. A potential cure for type 1 diabetes is the replacement of lost beta-cells by transplant. While effective, the number of available human beta-cell donors falls far short of the number of patients. Another potential source of beta-cells for transplant are cells created in the lab from stem cells. Two research groups, including our Diabetes Research Group at The University of British Columbia, recently reported major breakthroughs in the development of beta-cells from stem cells. Despite these advances, current protocols are still unable to generate fully mature beta-cells from stem cells. Therefore the aim of this project is to identify drugs that can aid the creation beta-cells from stem cells. The Johnson lab has previously developed a sophisticated imaging platform using robotic microscopes to allow for millions of cells to be imaged in parallel over time. We have also developed a virus-based probe that indicates the amount of insulin being produced by a cell, which is a marker of a beta-cell's maturity. We will combine our probe and imaging platform to screen thousands of drugs to identify ones that increase insulin production in cells created from stem cells. The top “hits” from our screen will be selected for more detailed follow up studies, after which they can be rapidly incorporated into clinical trial pipelines for transplant therapy.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
367167
Name
Kamal Sepehr
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Image-based screening to enhance insulin production in human embryonic stem cells
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Diabetes; Drug Screening; High-Content Imaging; Insulin; Pancreatic-Beta Cells; Regenerative Medicine; Stem Cells
Abstract
Type 1 diabetes is a disease where the body's immune system attacks and destroys the cells in the pancreas known as beta-cells, which produce insulin. The resulting loss of insulin causes high blood glucose levels that can lead to long-term complications such as heart disease and stroke. Current treatment for patients involves monitoring of blood glucose levels and insulin injections many times each day. A potential cure for type 1 diabetes is the replacement of lost beta-cells by transplant. While effective, the number of available human beta-cell donors falls far short of the number of patients. Another potential source of beta-cells for transplant are cells created in the lab from stem cells. Two research groups, including our Diabetes Research Group at The University of British Columbia, recently reported major breakthroughs in the development of beta-cells from stem cells. Despite these advances, current protocols are still unable to generate fully mature beta-cells from stem cells. Therefore the aim of this project is to identify drugs that can aid the creation beta-cells from stem cells. The Johnson lab has previously developed a sophisticated imaging platform using robotic microscopes to allow for millions of cells to be imaged in parallel over time. We have also developed a virus-based probe that indicates the amount of insulin being produced by a cell, which is a marker of a beta-cell's maturity. We will combine our probe and imaging platform to screen thousands of drugs to identify ones that increase insulin production in cells created from stem cells. The top “hits” from our screen will be selected for more detailed follow up studies, after which they can be rapidly incorporated into clinical trial pipelines for transplant therapy.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kamal, Sepehr
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~